
ResMed Inc.
ResMed Inc. (RMD) Free Cash Flow & Analysis
Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.
RMD · free cash flow · updated Jun 8, 2026
Core FCF metrics
RMD · FCF · TTM · margin & CAGRFree cash flow was $1.66B for FY2025 (fiscal year ending 2025-06-30), up 29.2% year-over-year The FCF margin was 32.3%. Five-year CAGR stands at +19.0%.
Annual free cash flow history
Annual free cash flow data
FCF valuation metrics
RMD · P/FCF · FCF yield · FCF per shareResMed Inc. (RMD) trades at a FCF yield of 6.22% and a price-to-free-cash-flow ratio of 16.2x. FCF per share stands at $11.96, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.
Cash flow statement summary
RMD · cash flow statement · operating / investing / financingFor FY2025, ResMed Inc. generated $1.75B in operating cash flow and spent 90M in capital expenditures, yielding $1.66B in free cash flow.
For the complete Operating / Investing / Financing line-item breakdown:
View Full Cash Flow Statement →Free cash flow vs peers (Healthcare)
About Free Cash Flow & Methodology
ResMed Inc. (RMD) reported free cash flow of $1.66B for FY2025 (fiscal year ending 2025-06-30), up 29.2% year-over-year. The FCF margin was 32.3%.
Based on available data, ResMed Inc. has maintained positive free cash flow for at least 15 fiscal year(s). FCF peaked at $1.66B in FY2025. The 5-year CAGR stands at +19.0%.
ResMed Inc.'s FCF yield is 6.22% and price-to-FCF ratio is 16.2x for FY2025, based on the latest available data.
Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.
Frequently asked questions
RMD free cash flow · 8 questionsResMed Inc. free cash flow was $1.66B for FY2025, up 29.2% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $1.75B.
▸ Source: FMP /cash-flow-statement · US GAAP · ResMed Inc. · ResMed Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026